Plasma concentrations of amino acids (AAs), in particular, branched chain AAs (BCAAs), are often found increased in nonalcoholic fatty liver disease (NAFLD); however, if this is due to increased muscular protein catabolism, obesity, and/or increased insulin resistance (IR) or impaired tissue metabolism is unknown. Thus, we evaluated a) if subjects with NAFLD without obesity (NAFLD-NO) compared to those with obesity (NAFLD-Ob) display altered plasma AAs compared to controls (CTs); and b) if AA concentrations are associated with IR and liver histology. Glutamic acid, serine, and glycine concentrations are known to be altered in NAFLD. Because these AAs are involved in glutathione synthesis, we hypothesized they might be related to the severity of NAFLD. We therefore measured the AA profile of 44 subjects with NAFLD without diabetes and who had a liver biopsy (29 NAFLD-NO and 15 NAFLD-Ob) and 20 CTs without obesity, by gas chromatography-mass spectrometry, homeostasis model assessment of insulin resistance, hepatic IR (Hep-IR; Hep-IR 5 endogenous glucose production 3 insulin), and the new glutamate-serine-glycine (GSG) index (glutamate/[serine 1 glycine]) and tested for an association with liver histology. Most AAs were increased only in NAFLD-Ob subjects. Only alanine, glutamate, isoleucine, and valine, but not leucine, were increased in NAFLD-NO subjects compared to CTs. Glutamate, tyrosine, and the GSG-index were correlated with Hep-IR. The GSG-index correlated with liver enzymes, in particular, gamma-glutamyltransferase (R 5 0.70), independent of body mass index. Ballooning and/or inflammation at liver biopsy were associated with increased plasma BCAAs and aromatic AAs and were mildly associated with the GSG-index, while only the new GSG-index was able to discriminate fibrosis F3-4 from F0-2 in this cohort. Conclusion: Increased plasma AA concentrations were observed mainly in subjects with obesity and NAFLD, likely as a consequence of increased IR and protein catabolism. The GSG-index is a possible marker of severity of liver disease independent of body mass index. (HEPATOLOGY 2018;67:145-158).
T he prevalence and incidence of nonalcoholic fatty liver disease (NAFLD) is increasing. (1) The mechanisms that favor the development of simple steatosis and the following transition to inflammation, ballooning, and fibrosis (i.e., nonalcoholic steatohepatitis [NASH] ) are still not well understood. In addition, it is necessary to identify novel biomarkers of altered mechanisms that can follow the progress of the disease. Metabolomics has provided insights into mechanisms underlying development of several diseases of insulin resistance (IR), such as type 2 diabetes mellitus (T2DM) and NAFLD, and has also led to the discovery of potential biomarkers of NAFLD and its severity. (2) (3) (4) (5) (6) (7) Among metabolites with increased amino acid (AA) concentrations, branched chain AAs (BCAAs), in particular, have been associated with an increased risk of metabolic disease, including T2DM and NAFLD. (8) (9) (10) However, some researchers question if AAs are really causally linked to T2DM and other metabolic diseases or if increased concentrations of AAs are due to prevailing IR or possibly impaired tissue metabolism. (9, 11, 12) Fasting plasma levels of BCAAs (i.e., leucine, isoleucine, and valine) are often found increased and associated with peripheral IR. (6, 8) Plasma concentrations of aromatic AAs (AAAs, e.g., tyrosine and phenylalanine) were also found increased with increased severity of liver diseases. (13) These results are not surprising because the liver is the site of protein and AA metabolism (both synthesis and catabolism) (Fig. 1) .
Patients with NAFLD have increased peripheral IR and hepatic IR (Hep-IR), (14) although the pathophysiologic mechanisms for increased Hep-IR in NAFLD are not known. AAs might mediate the activation of several hepatic metabolic pathways involved in insulin signaling and glucose regulation. (11) For example, it has been hypothesized that BCAAs might increase Hep-IR through mammalian target of rapamycin signaling. (8, 10, 15) However, because during fasting most circulating AAs derive from muscle catabolism, (16) which is increased in IR states, it is likely that an alteration in AA concentrations reflects IR rather than the presence of NAFLD. Most previous studies involved mainly subjects with obesity and IR, where AA catabolism is up-regulated, and thus it is not easy to establish if increased fasting concentrations of AAs are related to NAFLD or to peripheral IR. Studies in animals (e.g., Sunny et al. (15) ) have also been inconclusive because they compare age-matched animals treated with a high-fat diet (versus chow diet) without accounting for the increase in IR. In addition to BCAAs and AAAs, other AAs, such as glutamate, glutamine, alanine, and aspartate, have been found to be positively associated with increased cardiometabolic risk and particularly with Hep-IR, (12, (17) (18) (19) while glycine and serine were found decreased in metabolic diseases, including NAFLD. (19) (20) (21) (22) (23) Thus, the first aim of our study was to evaluate if plasma AA concentrations were increased/decreased similarly in subjects with and without obesity but with NAFLD and their association with the degree of fasting Hep-IR and peripheral IR. Our second aim was to evaluate if alterations in plasma AA concentrations (such as BCAAs, AAAs, glutamate, glycine, and serine), which alter cell function or are involved in mitochondrial function and oxidative stress, might reflect hepatic inflammation and/ or fibrosis.
Patients and Methods
We studied 44 patients without diabetes but with biopsy-proven NAFLD and 20 healthy controls (CTs) ( Table 1 ). All CTs had normal liver enzymes, normal liver at ultrasound scan, and low probability of hepatic fat according to noninvasive indexes (fatty liver index <20; NAFLD liver fat score >1.257). Patients with NAFLD were divided into without obesity (NAFLD-NO, body mass index [BMI] <30 kg/m 2 , n 5 29) and with obesity (NAFLD-Ob; BMI 30 kg/m 2 , n 5 15) groups.
Liver biopsy was scored as described. (24) The sum of grading for steatosis, lobular inflammation, and hepatocellular ballooning was used to calculate the NAFLD activity score from 0 to 8. Fibrosis was staged F0 to F4 and classified as absent (F0), mild (F1-2), and severe (F3-4). NASH was defined by the local pathologist according to the combined presence of steatosis, hepatocyte ballooning, and lobular inflammation with or without fibrosis. After subjects fasted overnight, we collected a blood sample from each to measure liver enzymes, lipid profile, and concentrations of glucose, free fatty acid, insulin, and AAs.
All subjects participated in the study after signing an informed consent. All other investigations were carried out during regular follow-up of NAFLD patients, according to specific protocols, and all patients gave their consent for including their personal data in the database. The study was approved by the ethics committee of the University Hospital San Giovanni Battista of Torino and was in accordance with the Helsinki Declaration.
MEASUREMENTS AND CALCULATIONS
Plasma concentrations of lipids, glucose, insulin, liver enzymes, and lipid profile were measured as reported. (25, 26) The AA plasma profile was evaluated on fasting samples by gas chromatography-mass spectrometry (Agilent Technology GC7890-MS5975). Briefly, 80 lL of an ethylene diamine tetraacetic acid FIG. 1. The hepatic metabolic pathway in which amino acids (in particular the components of the GSG-index glutamate, serine, and glycine) are involved. In the presence of NASH, inflammation and oxidative stress are increased. ROS stimulate the synthesis of GSH from glutamate, glycine, and cysteine. Once GSH reaches the cell surface, it is transaminated by GGT and glutamate is released into the bloodstream. Glutamate is also produced from transamination of alanine and aspartate. Abbreviations: 3PG, 3-phosphoglycerate; 3PHP, 3-3-phosphohydroxypyruvate; 3PS, 3-phosphoserine; 4-HPPA, 4-hydroxyphenylpyruvic acid; Acyl CoA, acetyl coenzyme A; ADP, adenosine diphosphate; ATP, adenosine triphosphate; CoA, coenzyme A; Cys, cysteine; DP, dispeptidase; FA, fatty acid; Glut, glutamate; Gly, glycine; GSSG, glutathione disulfide; a-KG, a-ketoglutarate; NAD1, oxidized nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine dinucleotide; OAA, oxaloacetate; PEP, phosphoenol-pyruvate; Phe, phenylalanine; Pi, inorganic phosphate; TAG, triacylglycerols; TCA, tricarboxylic acid cycle; Tyr, tyrosine.
plasma sample was deproteinized with 1 mL methanol and subsequently purified by ion exchange columns and derivatized using N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide (Sigma, USA). Plasma AA concentrations were determined using, as the internal standard, a mix of 13 C-labeled AAs (Celtone; CIL, Cambridge, MA) that contained uniformly labeled phenylalanine, tyrosine, leucine, isoleucine, valine, alanine, lysine, hystidine, proline, threonine, glutamate, serine, and glycine. Our method provides a quantitative analysis of the plasma AA profile as opposed to the usual metabolomics methods that are semiquantitative. Using this approach, we were able to quantify concentrations of AAAs phenylalanine and tyrosine; BCAAs leucine, isoleucine, and valine; and alanine, lysine, histidine, proline, threonine, glutamate, serine, and glycine (Table 2) .
We derived a new index based on the ratio of glutamate to serine plus glycine concentrations (glutamate/ [serine 1 glycine]), named the GSG-index. The concentrations of these AAs were previously found altered in metabolic diseases, including NAFLD (Table 3 ); in particular, glutamate concentrations were increased while glycine and serine were decreased. (19) (20) (21) (22) (23) These AAs are involved in the synthesis of glutathione (GSH) (glutamic acid and glycine directly, and serine indirectly because it is a precursor of glycine) and lipids associated with lipotoxicity (i.e., ceramides) (Fig. 1) . We therefore tested if the GSG-index was associated with alterations in liver histology.
INSULIN RESISTANCE
We quantified the degree of IR in liver and muscle (denominated peripheral IR). Hep-IR, which reflects the inability of insulin to suppress fasting endogenous glucose production (EGP), was calculated as Hep-IR 5 (EGP 3 fasting insulin). (27) EGP was measured by the kinetics of 6,6-D2-glucose infused for 2 hours during a fasting state, as reported, (25) in all subjects with NAFLD and in 8 CT subjects. Peripheral insulin sensitivity was calculated as the fasting glucose rate of disappearance (Rd) measured by the kinetics of 6,6-D2-glucose normalized by fasting insulin (Rd/I). (25) The homeostasis model assessment of insulin resistance (HOMA-IR), calculated as (glucose 3 insulin)/ 22.5, reflects both Hep-IR and peripheral IR, as described. (26, 28) We tested if the degree of IR was different in subjects with NAFLD with and without obesity and if the concentrations of AAs were altered differently in subjects with NAFLD with versus without obesity compared to CT subjects. 
STATISTICAL ANALYSIS
Variables were expressed as mean 6 SE. The difference between controls and NAFLD subjects was calculated using a parametric test (analysis of variance or t test) when normally distributed or using a nonparametric test (Mann-Whitney, Kruskal-Wallis) when variables were not normally distributed (StatView and JMP; SAS Institute Inc.). For correlation analysis, we used Pearson's correlation coefficient for normally distributed variables and Spearman's rank correlation for non-normally distributed variables. For multivariable correlation analysis, we reported the partial correlation coefficient. For the analysis of the association between AA concentrations and liver histology, AA concentrations in subjects with NAFLD were divided by the mean values observed in CTs and then log2-transformed to evaluate the fold changes compared to CTs. Statistical significance was tested using the Wilcoxon signed rank test. We used multivariable analysis to evaluate which among BCAAs, AAAs, and the GSG-index were independently associated with indexes of IR. We used logistic regression analysis to evaluate which among BCAAs, AAAs, and the GSG-index (used simultaneously as independent variables) had the highest odds ratio (OR) for ballooning grade 2, inflammation, or liver fibrosis (F3-4), taking into account BMI. All variables that were not normally distributed were log e -transformed before the analysis.
Results

CLINICAL CHARACTERISTICS OF THE STUDY SUBJECTS
The anthropometric, clinical, and biochemical parameters of the study population (NAFLD and CT) are summarized in Table 1 . Overall, BMI ranged from 18 to 36 kg/m 2 . However, the majority of NAFLD subjects (29 of 44) had a BMI <30 kg/m 2 ; the BMI of NAFLD-NO subjects was similar to that of the CTs (25.6 6 0.5 versus 24.1 6 0.8 kg/m2, respectively), and the difference was not significant. As expected, compared to the CT group, subjects with NAFLD had higher concentrations of liver enzymes (alanine aminotransferase [ALT], gamma-glutamyltransferase [GGT], aspartate aminotransferase [AST]; all P < 0.0001) ( Table 1) . IR was higher in the NAFLD-Ob group compared to the NAFLD-NO and CT subjects, both when calculated as HOMA-IR (4.7 6 0.7 versus 2.4 6 0.2 versus 1.8 6 0.2, respectively; P < 0.0001) and Hep-IR (166 6 23 versus 96 6 6 versus 52 6 6, respectively; P < 0.001) ( Table 1) .
When analyzed as a whole and compared to CTs, subjects with NAFLD had higher plasma levels of isoleucine and valine (BCAAs), tyrosine (AAA), alanine, lysine, and glutamate, while the plasma concentration of glycine was significantly decreased (all P < 0.03) ( Table 2 ). However, most AAs were increased only in the NAFLD-Ob group. Only alanine and glutamate, and among the BCAAs only isoleucine and valine, but not leucine, concentrations were increased in NAFLD-NO subjects compared to CTs (Table 2) . BCAAs and AAAs were also correlated with liver enzymes ALT (BCAAs, R 5 0.48, P < 0.0001; AAAs, R 5 0.37, P < 0.004), AST (BCAAs, R 5 0.25, P 5 0.04; AAAs, R 5 0.22 P 5 0.07), and GGT (BCAAs, R 5 0.42, P 5 0.0008; AAAs, R 5 0.31 P 5 0.01) (data not shown). Bianchi et al. (12) 39 biopsy-proven NAFLD and 10 control subjects Reduced serine and glycine in NAFLD. Greater suppression of BCAA and serine during insulin clamp, associated with higher M value Newgard et al. (8) 74 obese and 67 lean subjects with insulin resistance Increased BCAA, tyrosine, phenylalanine, alanine, glutamate/ glutamine, and decreased glycine in obese subjects
Kalhan et al. (6) Nondiabetic subjects with hepatic steatosis (n 5 11) or NASH (n 5 24) compared to healthy controls (n 5 25).
Higher levels of BCAA, phenylalanine, tyrosine, and glutamate, but lower plasma GSH and GSH metabolites in NASH Wang-Sattler et al. (22) Individuals who developed insulin resistance or T2D over 7 years
Decreased glycine concentration is predictor of impaired glucose tolerance and of T2D
Cheng et al. (17) Two cohorts free of diabetes Framingham Heart Study (n 5 1015); the Malmo Diet and Cancer Study (n 5 746) with a 12-year follow-up
Plasma glutamate concentration was strongly associated with insulin resistance and circulating TG. Low glutamine and high glutamate concentrations were associated with incidence of diabetes in the Framingham Heart Study.
Wurtz et al. (35) 1,873 Finnish individuals followed up for 6.5 years
Increased BCAA, phenylalanine, tyrosine, and reduced glycine were all associated with glycemia and insulin sensitivity at baseline and predictors of fasting and/or postchallenge glucose in this study
Floegel et al. (21) Two cohorts with a 7-year follow-up and diabetes-relevant traits
Higher plasma concentrations of phenylalanine, isoleucine, tyrosine, and valine were associated with increased risk of T2D and glycine was associated with reduced risk of T2D.
Lynch et al. (10) Review of current knowledge on the metabolic effects of BCAA
The authors conclude that "increased BCAA levels are more likely to be a marker of loss of insulin action and not, themselves, causative"
Mardinoglu et al. (23) Genome-scale metabolic model of liver in patients with NAFLD.
Nonessential amino acids serine, glycine, glutamate, glutamine, aspartate, asparagine, and alanine and essential amino acids valine and methionine are involved in the appearance of NASH. NASH patients have severe serine deficiency Lake et al. (32) Frozen liver from 17 healthy, 4 steatosis, 14 NASH fatty, and 23 NASH not fatty Increased BCAA and tyrosine and increased BCAT1 activity in liver of patients with NASH.
Palmer al. (38) 96 subjects from the Insulin Resistance Atherosclerosis Study at the extremes of the Insulin sensitivity distribution Decreased glycine and increased valine, leucine, and combined glutamine and glutamate was associated to conversion to T2D (76 converters; 70 nonconverters) Kawanaka et al. (34) 137 patients with NAFLD and liver biopsy Plasma BCAA levels, and BCAA-to-Tyr ratio values were negatively associated with the fibrosis stage, and Tyr levels increased with increasing fibrotic staging. Tyr levels were also correlated with HOMA-IR.
Hyotylainen, et al. (19) Measurements in the artery and the hepatic vein of 8 NAFLD and 8 healthy subjects
Increased fasting hepatic import/degradation of glycine, serine, tyrosine, cysteine and alanine and net release of glutamate, fatty acids, triglycerides, and glucose in NAFLD.
Mardinoglu et al. (20) 86 subjects with varying degrees of hepatic steatosis
Fasting plasma levels of glycine and serine showed significantly negative correlations with hepatic steatosis. Glycine and serine are the limiting substrates for the de novo synthesis of GSH Abbreviations: BCAT1, BCAA transaminase 1; TG, triglyceride; Tyr, tyrosine.
The GSG-Index
Alterations of glutamate, glycine, and serine often occur in metabolic diseases (Table 3 ) and were confirmed in this study. We first tested if the concentrations of these single AAs and/or the GSG-index (given by the ratio of Glutamate/[Serine 1 Glycine]) were altered in NAFLD. We found that glutamate concentrations were significantly higher and glycine concentrations lower in patients with NAFLD compared to CTs ( Table 2 ). The GSG-index was significantly higher in NAFLD-NO subjects compared to CTs and was even higher in NAFLD-Ob subjects (P < 0.002), but no correlation was found with BMI. On the other hand, the GSG-index was highly correlated with increased liver enzymes as a result of increased transamination, in particular, with GGT (R 5 0.70; P < 0.0001) but also with ALT and AST (R 5 0.42 and 0.40, respectively; P < 0.002) (Fig. 2) . We attribute this to GGT, but also ALT and AST, promoting glutamate release during transamination reactions (Fig. 1) . The GSG-index also correlated well with BCAAs, in particular, leucine, indicating an increased action of glutamate dehydrogenase (Fig. 2) . Glutamic acid alone was also associated, although less so, with liver function tests, while no association was found between liver function tests and the concentration of the other AAs that compose the index, i.e., glycine or serine.
AMINO ACIDS AND INSULIN RESISTANCE
Only a few AAs had a significant correlation with Hep-IR. Glycine and histidine had a significant inverse correlation with Hep-IR (Spearman's rank coefficient, R 5 -0.37, P 5 0.008; R 5 -0.29, P < 0.05, respectively), while positive correlations were found with glutamate (R 5 0.29, P < 0.04) and tyrosine (R 5 0.41, P 5 0.004). Only tyrosine (R 5 0.39, P < 0.002) correlated with HOMA-IR. Peripheral By using multivariable analysis, we evaluated which among BCAAs, AAAs, and the GSG-index were independently associated with Hep-IR and HOMA-IR. We found that both the GSG-index (partial R 5 0.33, P 5 0.021) and AAAs (partial R 5 0.32, P 5 0.027) were independently associated with Hep-IR (total R 5 0.47, P 5 0.008), while only AAAs (partial R 5 0.33, P 5 0.008) were independently associated with HOMA-IR (total R 5 0.44, P 5 0.006).
AMINO ACIDS AS MARKERS OF HEPATIC INFLAMMATION AND FIBROSIS
We tested which AA concentrations were altered in the presence of hepatic ballooning and inflammation. Compared to the CTs, NAFLD subjects with hepatocellular ballooning grade 2 had increased plasma concentrations of BCAAs, AAAs, glutamate, alanine, and lysine, while the concentrations of glycine and threonine were decreased (Fig. 3) . Similar results were found for inflammation, although the concentrations of alanine were also increased in subjects with inflammation grade 0 (Fig. 4) . AA concentrations were also associated with increased liver fibrosis (Fig. 5) , but concentrations observed in NAFLD subjects with fibrosis scores F3 and F4 were not significantly different than in those with fibrosis score F0-2.
The AAs used to calculate the GSG-index are in some way involved in the synthesis of GSH (glutamic acid and glycine directly, while serine indirectly because it is a precursor of glycine) and of lipids associated with lipotoxicity (i.e., ceramides) (Fig. 1) . We therefore tested if the GSG-index was associated with alterations in liver histology. Subjects with NAFLD had a higher GSG-index independent of the presence of ballooning or inflammation in liver biopsy. The GSG-index was significantly increased with the degree of liver fibrosis, in particular, with severe fibrosis F3-4, and the new index was able to discriminate NAFLD with F0-2 from F3-4 (P < 0.0004 versus CT; P < 0.04 versus F0-2) (Fig. 5) .
We used logistic regression analysis to evaluate which among BCAAs, AAAs, and the GSG-index were independently associated with ballooning, inflammation, or liver fibrosis. Compared to CTs, the GSGindex showed better discrimination compared to BCAAs and AAAs in subjects with inflammation (GSG-index, OR 5 36, P 5 0.01; BCAAs, OR 5 1.02 and AAAs, 1.01, P not significant), ballooning grade 2 (OR 5 28.5, P 5 0.03; OR 5 1.03 and 1.01, P not significant), and fibrosis F3-4 (OR 5 122, P 5 0.004; OR 5 1.04 and 1.00, P not significant). These results were confirmed after accounting for the different BMIs.
Discussion
NAFLD is a recognized risk factor for the development of T2DM and cardiovascular disease, and patients with T2DM have an increased risk of developing NAFLD. (29, 30) Most T2DM patients have NAFLD even in the presence of normal liver enzymes. (31) Moreover, there is high risk for these patients to develop cirrhosis and hepatocellular carcinoma. For this reason, it is important to identify circulating markers of NAFLD for an early discovery and treatment of subjects with this disease.
IMPACT OF INSULIN RESISTANCE ON PLASMA AMINO ACID CONCENTRATION
Plasma AA concentrations have been implicated in the pathogenesis of NAFLD and progression to NASH, but their causal role has not been established. AA concentrations are often found altered in metabolic diseases, including T2DM, NAFLD, and obesity, because they are also associated with IR. (4, 6, 9, 32) Several studies have found aromatic AAs (i.e., tyrosine and phenylalanine) increased in liver disease. (6, 33, 34) Phenylalanine is irreversibly converted to tyrosine mainly in the liver where tyrosine is further metabolized. Increased tyrosine concentrations are often detected in patients with NAFLD, (6, 34) possibly because of impairment in hepatic metabolism of this AA.
In the past decade, attention has been focused on circulating BCAAs that might play a role in promoting peripheral IR and Hep-IR (8, 9) and promote the onset of T2DM. (21, 35) However, increased BCAA concentrations might reflect impaired muscle rather than liver catabolism because BCAAs are metabolized principally in muscle. (10) In subjects with NAFLD, impaired suppression of BCAAs during hyperinsulinemic euglycemic clamp was proportional to impaired muscle glucose uptake during the clamp and peripheral IR. (12) Women with abdominal obesity, but not those with lower obesity, showed impaired suppression of leucine during the hyperinsulinemic euglycemic clamp procedure. (36) Thus, it is not clear if subjects with NAFLD have an altered hepatic metabolism of AAs or if AAs are increased because of obesity and IR, given that the majority of patients with NAFLD also have obesity. Consequently, we explored if the increased plasma concentration of AAs, in particular BCAAs, was a characteristic feature of all subjects with NAFLD or if AAs were altered in the presence of obesity and IR. We quantified plasma AA concentrations in subjects with NAFLD but without diabetes comparing subjects with obesity to those without and evaluated the impact of IR. We found subjects with NAFLD to be more insulin resistant than CT subjects when considered as a whole group; however, when divided according to the presence of obesity, the differences between NAFLD-NO subjects (i.e., those with BMI <30 kg/m 2 ) and CTs were reduced. Compared to CTs, subjects with NAFLD but without diabetes showed increased fasting values of glutamate, alanine, tyrosine, lysine, valine, and isoleucine, i.e., glucogenic AAs, but fewer AAs were increased in the NAFLD-NO group versus CTs, i.e., glutamate, alanine, valine, and isoleucine. When we evaluated the association with IR, Hep-IR correlated with most AAs, including BCAAs, AAAs, and GSG-index, while only tyrosine correlated with peripheral IR. We found glutamate and tyrosine increased while glycine and histidine decreased proportionally to Hep-IR. This is in agreement with previous studies that have often found glutamate and tyrosine increases in an insulin-resistant state, such as obesity, T2DM, prediabetes, and/or NAFLD, (21, 32, 37, 38) also related to increased oxidative stress (6, 9) as well as to liver disease. (19, 34) On the other hand, glycine (12, (19) (20) (21) 38) and serine were found decreased. (12, 23) A recent study of an analysis of splanchnic fluxes based on measurements in the artery and the hepatic vein showed that subjects with NAFLD have increased fasting hepatic import/degradation of glycine, serine, and alanine and a net release of glutamate, fatty acids, triglycerides, and glucose. (19) This remained true during insulin infusion. We therefore conclude that elevated AA concentrations observed in NAFLD are likely to be related to peripheral resistance to the anticatabolic effect of insulin that often accompanies defects in glucose metabolism and results in increased muscle proteolysis during the fasting state. This might explain some of the recent data on increased sarcopenia in subjects with NAFLD. (39, 40) 
AMINO ACIDS AND LIVER HISTOLOGY
Another important question is if AA concentrations are related to parameters of liver histology, such as inflammation, ballooning, and/or fibrosis. NAFLD/ NASH is characterized by hepatic inflammation not always associated with whole body inflammation, but only liver biopsy can identify subjects with liver inflammation because circulating markers are still lacking. Several AAs released from muscle or synthesized in the liver were previously implicated in NAFLD and the development of liver damage, among these BCAAs and AAAs. Thus, we hypothesized that alterations in plasma AA concentrations might help identify subjects with NAFLD and hepatic inflammation and/or liver damage (i.e., fibrosis). We found several plasma AA concentrations increased with inflammation and ballooning (Figs. 3 and 4) . Regarding liver fibrosis, glutamate was the AA that was more strongly associated with the severity of fibrosis (Fig. 5) . Glutamate is involved in many reactions. It is a product of AA transamination, and once converted to a-ketoglutate it enters the tricarboxylic acid (TCA) cycle; it is also a substrate for intracellular GSH synthesis and turnover (Fig. 1) . Once produced, GSH exits the cell where it can be transaminated back by GGT releasing glutamate into the circulation (Fig. 1) . However, one report showed that all hepatic enzymes linked to glutamate metabolism, except the cytosolic BCAA transaminase 1, were down-regulated in the liver of patients with NASH and were associated with increased circulating levels of glutamate. (23) This was confirmed in another study. (32) We also found that glutamate concentrations and the GSG-index increased in NAFLD and were strongly associated with GGT concentrations (Fig. 2) . Thus, glutamate might reflect an alteration in hepatic function possibly due to NASH, i.e., the presence of inflammation, ballooning, oxidative stress, and/or related to an increased demand in glutathione. Other AAs that participate in the synthesis of GSH have been found altered in NAFLD.
Studies have shown that metabolic dysregulation is often associated with a reduction in glycine and serine concentrations and an increase in the levels of valine and leucine. (21, 23, 38) In this cohort of subjects with NAFLD but without diabetes, we also found reduced concentrations of glycine and serine (a precursor of cysteine) and increased concentrations of glutamate, the last explained by the fact that as GSH is transaminated by GGT, glutamic acid becomes newly available, thus increasing its plasma concentration (Fig.  1) . Glycine also plays an important role in metabolic regulation, DNA methylation, intracellular redox balance, bile acid conjugation, and heme synthesis. (22) Recently, glycine was shown to be the limiting step for GSH synthesis. (20) Our hypothesis was that in NAFLD there is increased use of serine and glycine that determines lower plasma concentrations, while glutamate is increased due to increased transamination (Fig. 1) . We thus tested if the GSG-index (given by the ratio glutamate/[serine 1 glycine]) was increased with the severity of liver histology and in particular liver fibrosis.
THE GSG-INDEX
A second result of our study was the development of a new metabolomics index based on plasma concentrations of glutamate/(serine 1 glycine) that we call the GSG-index from the initials of the AAs. The GSG-index is composed of AAs that participate in the synthesis of GSH (Fig. 1) , which is supposedly increased in NAFLD/NASH. (6, 20) GSH is an antioxidant molecule produced by several tissues in response to oxidative stress and increased production of reactive oxygen species (ROS). (41, 42) Oxidative stress is one of the mechanisms responsible for liver damage and is characterized by mitochondrial dysfunction, impaired oxidation, and production of ROS. (43) This process increases the demand of GSH synthesis to counteract production of ROS by increasing intracellular GSH turnover. (17, 44, 45) Amino acids, like glycine, serine, and glutamate, are used for the synthesis of GSH (Fig. 1) . However, glutamate concentrations are often found increased in metabolic diseases (Table 3) . We attribute this to GGT promoting glutamate release during the transamination of GSH ( Fig. 1 and 2) .
We found the GSG-index correlated with Hep-IR and increased more in subjects with NAFLD and obesity than in those with NAFLD without obesity, although this was not significantly associated with BMI or the degree of liver steatosis. The GSG-index also correlated well with BCAAs, in particular, leucine, indicating a possible altered action of glutamate dehydrogenase that is responsible for the conversion of leucine and alanine to glutamate (Fig. 2) . Recent studies have confirmed the alteration of these three AAs in NAFLD. (19, 23) Preliminary data from our group indicate that the GSG-index is dynamic because chronic treatment with pioglitazone, a peroxisome proliferator-activated receptor gamma agonist known to improve IR and liver function and histology, (46) was able to reduce the GSG-index together with a reduction in liver enzymes. (47) Briefly, in the ACT NOW study, in which 441 subjects with impaired glucose tolerance were randomized to placebo plus diet or to pioglitazone plus diet for 2.4 years, the GSG-index was markedly reduced by pioglitazone proportionally to the reduction in IR in muscle, liver, and adipose tissue and in liver enzymes. This was evident especially in subjects that reversed to normal glucose tolerance; in subjects that developed diabetes, there was an increase or no change in the GSG-index. (47) 
STRENGTHS AND LIMITATIONS
One strength of our paper lies in the quantification of AA concentrations (by gas chromatography-mass spectrometry, using labeled internal standards) in subjects without obesity or diabetes and with biopsyproven NAFLD, thus avoiding the confounding effect of obesity, IR, and hyperglycemia. Moreover, we have provided direct measurement of Hep-IR, quantified using the stable isotope tracer technique. We provided evidence that alterations in concentrations depend on obesity and IR status because only a few AAs (valine, isoleucine, alanine, and glutamate) were significantly elevated in the NAFLD-NO group compared to CTs. We developed a new index based on the ratio of glutamate/(serine 1 glycine) that was independently associated with severe liver damage and was able to discriminate fibrosis F0-2 from F3-4 independent of BMI. Moreover, the GSG-index has the advantage (as a ratio) to be calculated in qualitative and semiquantitative studies, where appropriately labeled internal standards are not always used, and to be used as a metabolomics biomarker in future studies.
As a limitation, this study is cross-sectional, and the GSG-index needs to be evaluated in a prospective study. However, preliminary data from our group have shown that 2.4 years of treatment with pioglitazone decreases the GSG-index proportionally in relation to the improvement in insulin sensitivity (in muscle, liver, and adipose tissue) and to the decrease in liver enzymes. (47) In conclusion, increased plasma AA concentrations were observed more in subjects with NAFLD and obesity than in those without obesity and are strongly associated with increased IR. Subjects with more advanced liver damage display increased values of BCAAs (isoleucine, valine), an AAA (tyrosine), and the GSG-index (glutamate), but only the GSG-index was able to discriminate mild to severe liver fibrosis, thus becoming a possible biomarker of severity of liver disease.
